美國Emergent BioSolutions www.emergentbiosolutions.com
Emergent BioSolutions公司是一家生物制藥企業(yè)，致力于免疫相關(guān)生物產(chǎn)品的開發(fā)、生產(chǎn)和商業(yè)化，其產(chǎn)品包括疫苗和療法，能幫助人體免疫系統(tǒng)預(yù)防或治療疾病。Emergent的上市產(chǎn)品BioThrax® （炭疽吸附疫苗）是美國食品藥品管理局（FDA）唯一認可的預(yù)防炭疽感染的疫苗。Emergent公司準備啟動和已經(jīng)啟動的開發(fā)項目中還有側(cè)重于炭疽、肉毒中毒、傷寒、結(jié)核、乙肝和衣原體的一些計劃。

Emergent BioSolutions Inc. is a leading biopharmaceutical company dedicated to one simple mission —to protect life. We develop, manufacture and commercialize immune related biologics, vaccines and biotherapeutics that assist the body’s immune system to prevent or treat infectious and other life threatening diseases. Our marketed product, BioThrax® (Anthrax Vaccine Adsorbed), is the only vaccine licensed by the U.S. Food and Drug Administration for the prevention of anthrax infection. Our product pipeline also includes: two “next generation” anthrax vaccines, two anthrax therapeutics (immunoglobulin and monoclonal), two botulinum vaccines and a botulinum therapeutic, an oral typhoid vaccine, a next generation tuberculosis vaccine, a hepatitis B immunotherapy, and a chlamydia vaccine.